Health Catalyst, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Health Catalyst, Inc. on August 10, 2021, reporting an event that occurred on August 13, 2021. The filing details the completion of an underwritten public offering of the company's common stock.
Key Financial Metrics
The filing reports the following specific financial data related to the capital raise:
- Shares Issued: 4,245,283 shares of Common Stock ($0.001 par value).
- Net Proceeds: Approximately $213.1 million (after deducting underwriting discounts, commissions, and estimated expenses).
- Underwriters: J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC, and Evercore Group L.L.C.
The filing does not provide data on revenue, profit, operating cash flow, margins, existing debt levels, or general liquidity metrics outside of the proceeds from this specific transaction.
Material Changes
The primary material change is the increase in the company's cash position due to the net proceeds of $213.1 million from the secondary offering. Additionally, the company is subject to a 60-day lock-up period (ending October 9, 2021) restricting the sale or transfer of Common Stock or convertible securities without the written consent of J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC.
Outlook, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on future operations, or a discussion of general business risks. The primary contingency noted is the indemnification agreement with the underwriters, under which the Company agreed to indemnify them against certain liabilities, including those under the Securities Act of 1933.
Key Facts for Investor Verification
- Verify the final use of the $213.1 million in net proceeds as disclosed in subsequent filings or press releases.
- Confirm the impact of the 60-day lock-up agreement on potential near-term share dilution or secondary sales.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific terms regarding indemnification and representations.
- Check subsequent 10-Q or 10-K filings to see how this capital raise affects the company's overall liquidity and debt-to-equity ratios.